A Randomized, Partially Blind Active Controlled Study to Evaluate the Immunogenicity of MEDI8662 in Adults 18 to 49 Years of Age

Trial Profile

A Randomized, Partially Blind Active Controlled Study to Evaluate the Immunogenicity of MEDI8662 in Adults 18 to 49 Years of Age

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jan 2012

At a glance

  • Drugs MEDI 3250 (Primary) ; Influenza virus vaccine live
  • Indications Influenza A virus H1N1 subtype; Influenza B virus infections; Influenza virus infections
  • Focus Pharmacodynamics
  • Sponsors MedImmune
  • Most Recent Events

    • 12 Jan 2012 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 12 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Oct 2010 Results presented at the 48th Annual Meeting of the Infectious Diseases Society of America.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top